Modeling of Survival and Frequency of Cardiovascular-Related Hospitalization in Patients with Transthyretin Amyloid Cardiomyopathy Treated with Tafamidis

INTRODUCTION: ATTR-ACT (Tafamidis in Transthyretin Cardiomyopathy Clinical Trial) demonstrated the efficacy and safety of tafamidis in transthyretin amyloid cardiomyopathy (ATTR-CM). Model-based analyses from ATTR-ACT can examine predictor effects on dose–response/exposure–response relationships. ME...

Descripción completa

Detalles Bibliográficos
Autores principales: Vong, Camille, Boucher, Martin, Riley, Steve, Harnisch, Lutz O.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8435516/
https://www.ncbi.nlm.nih.gov/pubmed/33770392
http://dx.doi.org/10.1007/s40256-021-00464-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8435516/
https://www.ncbi.nlm.nih.gov/pubmed/33770392
http://dx.doi.org/10.1007/s40256-021-00464-y

Ejemplares similares